A topical male contraceptive gel, NES/T, has moved closer to FDA approval following promising Phase III trial results. Applied daily to the shoulders, the gel suppresses sperm production by combining Nestorone (a progestin) and testosterone. In trials involving over 400 couples, the gel was 96% effective in preventing pregnancy, with minimal side effects like mild skin irritation.
This development marks a significant shift in contraceptive responsibility, traditionally borne by women. Surveys indicate that over 60% of men would be willing to use hormonal contraception if available, yet options have been limited to condoms and vasectomies. If approved, NES/T could hit the market by mid-2026, offering a reversible, non-invasive alternative.
Critics, however, question whether men will adhere to daily application, given past challenges with compliance in clinical settings. Additionally, some health experts raise concerns about long-term hormonal effects, though trial data so far shows no serious risks. Advocates argue that expanding male contraception could reduce unintended pregnancies and promote gender equity in reproductive health.
You Might Be Interested In:
- What is Nausea and Vomiting During Pregnancy?
- Have You Noticed a Loss of Appetite or Sudden Food Aversions?
- What is Sudden Sharp Pains in the Lower Abdomen During Pregnancy?
